Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR 1,704.60
+9.50 (0.56%)
At close: Feb 9, 2026
NSE:SUNPHARMA Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 109,290 | 95,764 | 84,736 | 32,727 | 29,038 |
Depreciation & Amortization | 25,073 | 24,906 | 24,771 | 21,090 | 20,296 |
Other Amortization | 681.2 | 661.7 | 533.4 | 435.8 | 503.9 |
Loss (Gain) From Sale of Assets | 235.3 | 1,662 | 227.1 | 1,656 | 16.7 |
Asset Writedown & Restructuring Costs | - | -1.5 | -10 | -88.7 | - |
Loss (Gain) From Sale of Investments | -2,514 | -921.9 | 6.2 | 3,126 | -2,596 |
Provision & Write-off of Bad Debts | 1,808 | 905.9 | 2,071 | 175.7 | 43.1 |
Other Operating Activities | 9,383 | -12,248 | -6,122 | 15,133 | -11,239 |
Change in Accounts Receivable | -16,021 | 3,529 | -9,532 | -13,423 | 937.3 |
Change in Inventory | -1,840 | 5,988 | -12,022 | 3,070 | -10,803 |
Change in Accounts Payable | 5,280 | 2,497 | 11,824 | 3,699 | 3,815 |
Change in Other Net Operating Assets | 9,345 | -1,393 | -46,888 | 22,244 | 31,692 |
Operating Cash Flow | 140,721 | 121,350 | 49,593 | 89,845 | 61,704 |
Operating Cash Flow Growth | 15.96% | 144.69% | -44.80% | 45.61% | -5.86% |
Capital Expenditures | -21,286 | -22,018 | -20,856 | -14,950 | -11,701 |
Sale of Property, Plant & Equipment | 610.1 | 308.4 | 210.1 | 606.1 | 971 |
Cash Acquisitions | -2,728 | -1,433 | -46,858 | -7,396 | -616 |
Divestitures | - | - | - | 238.4 | - |
Investment in Securities | -38,642 | 9,325 | -16,436 | -37,911 | 13,733 |
Other Investing Activities | 8,698 | 7,123 | 4,503 | 2,101 | 2,094 |
Investing Cash Flow | -53,062 | -6,902 | -79,437 | -57,247 | 5,362 |
Short-Term Debt Issued | - | 1,430 | - | 1,064 | - |
Long-Term Debt Issued | 33,617 | 45,727 | 81,598 | 16,568 | 66,029 |
Total Debt Issued | 33,617 | 47,157 | 81,598 | 17,632 | 66,029 |
Short-Term Debt Repaid | -482 | - | -1,305 | - | -1,726 |
Long-Term Debt Repaid | -44,784 | -82,287 | -30,010 | -45,286 | -109,199 |
Total Debt Repaid | -45,266 | -82,287 | -31,315 | -45,286 | -110,925 |
Net Debt Issued (Repaid) | -11,649 | -35,130 | 50,283 | -27,654 | -44,896 |
Repurchase of Common Stock | - | - | - | - | -559.5 |
Common Dividends Paid | -36,140 | -28,982 | -25,189 | -21,589 | -15,595 |
Other Financing Activities | -31,270 | -2,990 | -1,333 | -2,692 | 1,246 |
Financing Cash Flow | -79,058 | -67,102 | 23,761 | -51,935 | -59,805 |
Foreign Exchange Rate Adjustments | 1,230 | -739.9 | 1,571 | 1,274 | -1,297 |
Miscellaneous Cash Flow Adjustments | -0.3 | 12.9 | 5,667 | 414.5 | - |
Net Cash Flow | 9,831 | 46,619 | 1,155 | -17,648 | 5,964 |
Free Cash Flow | 119,435 | 99,332 | 28,738 | 74,895 | 50,002 |
Free Cash Flow Growth | 20.24% | 245.65% | -61.63% | 49.78% | -0.25% |
Free Cash Flow Margin | 22.72% | 20.48% | 6.55% | 19.38% | 14.93% |
Free Cash Flow Per Share | 49.78 | 41.40 | 11.98 | 31.21 | 20.84 |
Cash Interest Paid | 2,238 | 2,190 | 1,325 | 732.1 | 1,443 |
Cash Income Tax Paid | 4,768 | 15,694 | 15,098 | -9,692 | 10,029 |
Levered Free Cash Flow | 82,397 | 75,828 | 7,911 | 75,693 | 84,289 |
Unlevered Free Cash Flow | 83,843 | 77,318 | 8,986 | 76,489 | 85,173 |
Change in Working Capital | -3,236 | 10,621 | -56,618 | 15,591 | 25,641 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.